Go­ing where PRO­TACs can't, Ver­sant un­veils $50M bet on Car­olyn Bertozzi's LY­TAC tech — with a ris­ing star at the helm

When the first pro­tein degra­da­tion com­pa­nies an­nounced them­selves to the biotech world around 2013, wield­ing PRO­TACs — pro­te­ol­y­sis tar­get­ing chimeras — they promised to break the rules …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.